Provided by Tiger Trade Technology Pte. Ltd.

Sana Biotechnology, Inc.

3.26
-0.3000-8.43%
Post-market: 3.330.0700+2.15%19:57 EDT
Volume:4.53M
Turnover:15.15M
Market Cap:907.23M
PE:-3.54
High:3.59
Open:3.52
Low:3.25
Close:3.56
52wk High:6.55
52wk Low:1.60
Shares:278.29M
Float Shares:180.00M
Volume Ratio:2.01
T/O Rate:2.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9199
EPS(LYR):-0.9642
ROE:-118.70%
ROA:-26.00%
PB:5.64
PE(LYR):-3.38

Loading ...

Sana Biotechnology announces SC451 strategic collaboration with Mayo Clinic

TIPRANKS
·
Apr 14

Sana Biotechnology Inc - Sells 7.5 Mln Shares to Mayo Clinic at $3.33 per Share for $25 Mln - SEC Filing

THOMSON REUTERS
·
Apr 14

Sana Biotechnology sells 7,507,507 shares to Mayo Clinic for USD 25 million

Reuters
·
Apr 14

Sana Biotechnology, Mayo Clinic form strategic collaboration on type 1 diabetes cell therapy SC451

Reuters
·
Apr 14

Sana Biotechnology files Form 3; EVP and Chief Scientific Officer Dhavalkumar Dhirajlal Patel reports 99,510 common shares owned directly

Reuters
·
Mar 28

BUZZ - US STOCKS ON THE MOVE-Kyivstar Group, Applied Materials, Tevogen Bio

Reuters
·
Mar 14

Durable HIP Technology Data De‑Risks Sana Biotechnology’s SC451 Program and Supports Buy Rating

TIPRANKS
·
Mar 14

BUZZ-Sana Biotechnology rises as cell transplant shows promise in type 1 diabetes treatment

Reuters
·
Mar 13

Sana announces follow-up results from first-in-human study transplanting UP421

TIPRANKS
·
Mar 13

Sana reports positive 14-month results from UP421 hypoimmune islet transplant study in type 1 diabetes

Reuters
·
Mar 13

Sana Biotechnology Inc - Hip-Modified Islets Show Safety, Immune Evasion, and Insulin Production at 14 Months

THOMSON REUTERS
·
Mar 13

Sana Biotechnology Inc - No Safety Issues Identified in up421 Islet Cell Study

THOMSON REUTERS
·
Mar 13

Sana Biotechnology Inc - Expects to File Ind and Initiate Phase 1 Trial for Sc451 This Year

THOMSON REUTERS
·
Mar 13

Sana Biotechnology: Advancing T1D and In Vivo CAR-T Programs with 2026 Catalysts and Solid Cash Runway Supporting Buy Rating

TIPRANKS
·
Mar 07

Stock Track | Sana Biotechnology Plummets 5.24% Intraday on AI Adoption Risk Disclosure

Stock Track
·
Mar 05

AI Adoption Exposes Sana Biotechnology to Rising Data, Compliance, and Reputational Risks

TIPRANKS
·
Mar 05

Stock Track | Sana Biotechnology Plummets 5.09% Intraday After H.C. Wainwright Cuts Price Target

Stock Track
·
Mar 04

Sana Biotechnology Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 04

Sana Biotechnology: Emerging Clinical Validation and 2026 Pivotal Milestones Underpin Buy Rating

TIPRANKS
·
Mar 04

Sana Biotechnology, Inc. : H.c. Wainwright Cuts Target Price to $7 From $9

THOMSON REUTERS
·
Mar 04